SOURCE: CLX Investment Company, Inc.

November 15, 2006 09:48 ET

CLX Investment Company Announces Beginning of Zonda, Inc.'s Exhibit at MEDICA Trade Event

TEMECULA, CA -- (MARKET WIRE) -- November 15, 2006 -- CLX Investment Company, Inc. (OTCBB: CLXN), a diversified investment fund, today announced that portfolio investment Zonda, Incorporated has begun its exhibit at MEDICA, billed as the world's largest medical trade fair, which is being held this week in Dusseldorf, Germany. Zonda's contingent at MEDICA includes company president Laurie J. Oleksiewicz and director of European sales Pavel Holik.

The MEDICA trade fair, titled the 38th World Forum for Medicine (www.medica.de), is scheduled to feature over 4,200 exhibitors from 67 countries around the world showing the latest in medical products and medical-technical devices and systems. Over 137,000 visitors attended the 2005 MEDICA World Forum for Medicine, where Zonda exhibited its HandiLab line of medical diagnostic tests, and the Congress is expected to host a larger number of visitors this year.

"The annual appearance at MEDICA affords Zonda's management team an excellent opportunity to not only showcase its HandiLab tests but to also meet directly with its major European distributors," stated Robert McCoy, chairman and chief executive officer of CLX Investment Company. "Europe continues to be an extremely important market for Zonda, and we expect that this event will result in an even greater level of interest in both in Europe and around the world. MEDICA is a major worldwide medical industry gathering point, and Zonda will use its exhibit there to expand the profile of its HandiLab products to a broad industry audience. Last year's MEDICA exhibit was a great success, and we anticipate that Zonda's presence at this year's fair will be similarly fruitful."

Zonda's HandiLab-C test for chlamydia carries a CE mark for both professional point-of-care and over-the-counter use, which signifies that it complies with the relevant health, safety, environmental protection requirements in Europe and can therefore be legally placed on the market. Zonda's gonorrhea, yeast and Group A Strep tests carry CE marks for professional point-of-care use.

MEDICA's exhibit range includes electromedical equipment, medical technology, laboratory equipment, rescue and emergency equipment, diagnostics, drugs, physiotherapy, orthopedic technology, single-use products and consumer goods.

The MEDICA Congress also includes a total of approximately 200 certified seminars and training courses -- a recognized platform for the presentation of the latest scientific findings and a forum for knowledge transfer so as to put theory into medical practice. The Congress lectures range from prevention to rehabilitation, from homeopathic methods to high-tech medicine, from state-of-the-art diagnostics to targeted therapies. 2006 will see the following focal themes: cardiology, gastroenterology, oncology, metabolic disorders, infectiology and imaging processes as well as neurological topics including polyneuropathies, depression and dementia disorders.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.asp.

About Zonda, Incorporated

Zonda, Inc. (www.zondaincusa.com), in which CLX holds a 31% equity interest, specializes in diagnostic tests that serve the medical, food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. Zonda's product line includes innovative, rapid, self-contained diagnostic devices for the detection of chlamydia, gonorrhea, yeast (Candida albicans) and Group A Strep, tests that detect bacterial and other potential harmful micro-organisms on surfaces, and confirmation tests for a wide variety of bacteria. Each of the Zonda infectious disease tests are marketed as superior to their competition due to their comparable accuracy (compared directly to PCR or DNA testing), ease of use, compact design, long shelf life, rapid results, and cost effectiveness.

About CLX Investment Company

CLX Investment Company (www.clxinvestments.com) holds a 31% equity interest in Zonda, Inc. (www.zondaincusa.com). CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

CLX has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    951-587-8072
    Email Contact